한글목차

지혈제 시장 규모는 2023년에 27억 달러에 달할 것으로 보이고 있으며, 예측 기간 중 CAGR은 6.7%로 확대하며, 2028년에는 37억 달러에 달할 것으로 예측되고 있습니다.

노인 인구는 외과수술에 대한 수요가 증가하는 인구 집단으로, 현대 의료에서 지혈제의 중요한 필요성이 부각되고 있습니다. 고령화가 진행됨에 따라 많은 질병과 만성질환에 대한 감수성이 높아져 전반적인 삶의 질을 유지 및 개선하기 위해 외과적 개입이 필요한 경우가 많아집니다. 이러한 외과적 개입은 정형외과적 관절 치환술, 복잡한 심장 수술, 복잡한 소화기 수술 등 다양한 범위에 걸쳐 있습니다. 노화에 따른 조직의 탄력성 감소와 출혈에 대한 취약성 증가와 같은 생리적 변화를 고려할 때, 지혈제의 정확하고 효율적인 사용은 고령 환자의 외과적 치료에 있으며, 가장 중요한 의미를 갖는다. 세계 노인 인구가 꾸준히 증가함에 따라 지혈제에 대한 수요는 비례적으로 증가할 것으로 예상되며, 수술 치료를 받는 노인의 섬세한 헬스케어 요구를 충족시키는 데 있으며, 지혈제의 필수적인 역할이 강조되고 있습니다.

지혈제 시장은 유형별로 산화재생셀룰로오스계 지혈제, 트롬빈계 지혈제, 복합지혈제, 젤라틴계 지혈제, 콜라겐계 지혈제, 기타 지혈제로 구분됩니다. 지혈제 시장에서는 복합 지혈제가 크게 성장하고 있습니다. 복합 지혈제는 단일 지혈제보다 지혈 효과가 더 높은 경우가 많습니다. 이는 각기 다른 유형의 지혈제의 장점을 함께 가지고 있기 때문입니다.

세계 지혈제 시장은 매트릭스 및 젤 지혈제, 시트 및 패드 지혈제, 스펀지 지혈제, 분말 지혈제로 나뉩니다. 현재 지혈제 시장에서 가장 높은 성장률을 보이고 있는 것은 스펀지 지혈제입니다. 시장 성장의 주요 원인은 스펀지 지혈제와 관련된 다양한 장점으로 인해 최종사용자들에게 받아들여지고 있기 때문입니다.

아시아태평양 시장은 예측 기간 중 가장 높은 성장률을 보일 것으로 예상됩니다. 이 지역의 신흥 국가들은 GDP 성장과 가처분 소득 수준이 크게 증가하고 있습니다. 이로 인해 더 많은 인구의 의료비 지출이 증가하고 있습니다. 이 외에도 아시아태평양의 만성질환 유병률 및 이환율 증가, 수술 부담 증가, 의료 인프라의 현대화, 첨단 기술(특히 농촌 지역)의 보급 확대 등의 요인도 이 지역 지혈제 기업에게 큰 성장 기회를 제공할 것으로 보입니다. 기타 성장 요인으로는 질병 관리에 대한 인식을 높이기 위한 정부의 구상과 인도와 중국의 병원 및 진료소 증가 등이 있습니다. 아시아 국가들의 의료비 지출도 크게 증가하고 있습니다. 의료비 증가는 의료 서비스 프로바이더의 구매력을 높이고 지혈기구를 포함한 고급 의료 및 수술 용품의 채택을 촉진합니다.

세계의 지혈제 시장에 대해 조사했으며, 유형별, 제형별, 용도별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 중요 인사이트

제5장 시장 개요

• 서론
• 시장 역학
• 가격 분석
• 밸류체인 분석
• 공급망 분석
• 특허 분석
• 무역 분석
• 에코시스템 분석
• Porter's Five Forces 분석
• 규제 상황
• 기술 분석
• 고객의 비즈니스에 영향을 미치는 동향/혼란

제6장 지혈제 시장, 유형별

• 서론
• 개요
• 산화 재생 셀룰로오스 기반
• 트롬빈 기반
• 병용형
• 젤라틴 기반
• 콜라겐 기반
• 기타

제7장 지혈제 시장, 제형별

• 서론
• 매트릭스·겔
• 시트·패드
• 스펀지
• 분말

제8장 지혈제 시장, 용도별

• 서론
• 개요
• 정형외과
• 일반 외과
• 신경외과
• 심장혈관 외과
• 재건 수술
• 부인과 수술
• 기타

제9장 지혈제 시장, 지역별

• 서론
• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카

제10장 경쟁 구도

• 개요
• 주요 참여 기업의 전략/유력 기업
• 매출 분석
• 시장 점유율 분석
• 기업 평가 매트릭스
• 신규 기업/중소기업 평가 매트릭스
• 경쟁 시나리오

제11장 기업 개요

• 주요 참여 기업
  • JOHNSON & JOHNSON
  • BAXTER INTERNATIONAL
  • PFIZER INC.
  • B. BRAUN SE
  • BECTON, DICKINSON AND COMPANY
  • TELEFLEX INCORPORATED
  • MEDTRONIC PLC
  • HEMOSTASIS, LLC
  • STRYKER CORPORATION
  • INTEGRA LIFESCIENCES
  • ADVANCED MEDICAL SOLUTIONS GROUP PLC
  • SAMYANG HOLDINGS CORPORATION
• 기타 기업
  • MARINE POLYMER TECHNOLOGIES, INC.
  • GELITA MEDICAL GMBH
  • DILON TECHNOLOGIES, INC.
  • BETATECH MEDICAL
  • MERIL LIFE SCIENCES PVT. LTD.
  • BIOCER ENTWICKLUNGS-GMBH
  • UNILENE
  • KATSAN MEDICAL DEVICES
  • TRICOL BIOMEDICAL
  • 3-D MATRIX MEDICAL TECHNOLOGY
  • HEMOSTAT MEDICAL GMBH
  • MEDTRADE PRODUCTS LIMITED
  • ALTAYLAR MEDICAL

제12장 부록

영문목차

The hemostats market is valued at an estimated USD 2.7 billion in 2023 and is projected to reach USD 3.7 billion by 2028 at a CAGR of 6.7% during the forecast period. The geriatric population represents a demographic segment with a rising demand for surgical procedures, thus underscoring the critical need for hemostatic agents in modern healthcare. Advancing age brings an increased susceptibility to a multitude of medical conditions and chronic diseases, often necessitating surgical interventions to sustain or enhance the overall quality of life. These surgical interventions span a wide spectrum, encompassing orthopedic joint replacements, intricate cardiac procedures, and complex gastrointestinal surgeries. Given the physiological transformations inherent to aging, including diminished tissue elasticity and heightened vulnerability to hemorrhages, the precise and efficient utilization of hemostatic agents assumes paramount significance in the surgical care of elderly patients. As the global geriatric population continues its steady expansion, the requirement for hemostats is anticipated to amplify proportionally, thus emphasizing their indispensable role in addressing the nuanced healthcare needs of elderly individuals undergoing surgical treatments.

"Combination hemostats segment accounted for the highest growth rate in the hemostats market, by type, during the forecast period."

The hemostats market is bifurcated into oxidized regenerated cellulose-based hemostats, thrombin-based hemostats, combination hemostats, gelatin-based hemostats, collagen-based hemostats, and other hemostats on the basis of type. The combination hemostats segment in the hemostats market is experiencing substantial growth. Combination hemostats are often more effective at achieving hemostasis than single-agent hemostats. This is because they combine the strengths of different types of hemostats.

"Sponge hemostats segment accounted for the highest growth rate in the hemostats market, by formulation, during the forecast period."

The global hemostats market is bifurcated into matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, and powder hemostats. The sponge hemostats segment is currently witnessing the highest growth rate within the hemostats market. Market growth can largely be attributed to the growing acceptance of these formulations by end users due to the various advantages associated with them.

"Asia Pacific: The fastest-growing region hemostats market"

The global hemostats market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to witness the highest growth during the forecast period. Emerging countries in this region are witnessing growth in their GDPs and a significant rise in disposable income levels. This has led to increased healthcare spending by a larger population base. Other factors such as the increasing incidence & prevalence of chronic diseases, increasing burden of surgical procedures, healthcare infrastructure modernization, and the rising penetration of cutting-edge technologies (especially in rural areas) in Asia Pacific countries are also expected to provide significant growth opportunities for hemostats companies in this region. Also, other factors contributing to the growth include government efforts to increase awareness about the management of diseases and the increasing number of hospitals and clinics in India and China. The healthcare expenditure in Asian countries has also increased drastically. Growth in healthcare expenditure serves to increase the purchasing power of healthcare providers and stimulate the adoption of advanced medical/surgical supplies, including hemostats, in the region.

The break-up of the profile of primary participants in the hemostats market:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

The key players in this market are Johnson & Johnson (US), Baxter International (US), Pfizer Inc. (US), B. Braun SE (Germany), Becton, Dickinson and Company (US), Teleflex Incorporated (US), Medtronic Plc (Ireland), Hemostasis, LLC (US), Stryker Corporation (US), Integra LifeSciences (US), Advanced Medical Solutions Group Plc (UK), Samyang Holdings Corporation (South Korea), Marine Polymer Technologies, Inc. (US), GELITA MEDICAL GmbH (Germany), Dilon Technologies, Inc. (US), Betatech Medical (Turkey), Meril Life Sciences Pvt. Ltd. (India), BioCer Entwicklungs-GmbH (Germany), Unilene (US), Katsan Medical Devices (Turkey), Tricol Biomedical (US), 3-D Matrix Medical Technology (Japan), Hemostat Medical GmbH (Germany), Medtrade Products Limited (UK), and Altaylar Medical (Turkey).

Research Coverage:

This research report categorizes the hemostats market by type (thrombin-based hemostats, oxidized regenerated cellulose-based hemostats, combination hemostats, gelatin-based hemostats, collagen-based hemostats, and other hemostats), formulation (orthopedic surgery, general surgery, neurological surgery, cardiovascular surgery, reconstructive surgery, and gynecological surgery, and other surgical applications), application (matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, and powder hemostats), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the hemostats market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches and recent developments associated with the hemostats market. Competitive analysis of upcoming startups in the hemostats market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall hemostats market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (growing volume of surgical procedures performed, rising focus on R&D, and rising focus on effective blood loss management in patients during surgeries), restraints (side effects and allergic reactions associated with hemostats), opportunities (growth opportunities in emerging economies and growing number of hospitals), and challenges (stringent regulatory framework, dearth of skilled personnel for effective use of hemostats, and high cost of hemostats) influencing the growth of the hemostats market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the hemostats market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the hemostats market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the hemostats market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Johnson & Johnson (US), Baxter International (US), Pfizer Inc. (US), B. Braun SE (Germany), and Becton, Dickinson and Company (US), among others in the hemostats market strategies

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 STUDY SCOPE
  • 1.3.1 HEMOSTATS MARKET
  • 1.3.2 GEOGRAPHIC SCOPE
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY
• 1.5 LIMITATIONS
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • FIGURE 1 HEMOSTATS MARKET: RESEARCH DESIGN METHODOLOGY
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Primary sources
    • 2.2.2.2 Key data from primary sources
    • 2.2.2.3 Key industry insights
    • 2.2.2.4 Breakdown of primary interviews
  • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Approach 1: Company revenue estimation approach
  • FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
    • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.3.1.3 Growth forecast
    • 2.3.1.4 CAGR projections
  • FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • 2.3.2 TOP-DOWN APPROACH
  • FIGURE 6 HEMOSTATS MARKET: TOP-DOWN APPROACH
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • FIGURE 7 DATA TRIANGULATION METHODOLOGY
• 2.5 MARKET SHARE ANALYSIS
• 2.6 STUDY ASSUMPTIONS
• 2.7 GROWTH RATE ASSUMPTIONS
• 2.8 RISK ASSESSMENT
  • 2.8.1 RISK ASSESSMENT: HEMOSTATS MARKET
• 2.9 RECESSION IMPACT

3 EXECUTIVE SUMMARY

• FIGURE 8 HEMOSTATS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
• FIGURE 9 HEMOSTATS MARKET, BY FORMULATION, 2023 VS. 2028 (USD MILLION)
• FIGURE 10 HEMOSTATS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
• FIGURE 11 HEMOSTATS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS

• 4.1 HEMOSTATS MARKET OVERVIEW
  • FIGURE 12 GROWING NEED TO MANAGE BLOOD LOSS IN PATIENTS DURING SURGICAL PROCEDURES TO DRIVE MARKET GROWTH
• 4.2 HEMOSTATS MARKET SHARE, BY TYPE, 2023 VS. 2028
  • FIGURE 13 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS TO CONTINUE TO DOMINATE MARKET IN 2028
• 4.3 HEMOSTATS MARKET SHARE, BY FORMULATION, 2023 VS. 2028
  • FIGURE 14 MATRIX & GEL HEMOSTATS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
• 4.4 HEMOSTATS MARKET SHARE, BY APPLICATION, 2023 VS. 2028
  • FIGURE 15 ORTHOPEDIC SURGERY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• 4.5 HEMOSTATS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN HEMOSTATS MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • FIGURE 17 HEMOSTATS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing volume of surgical procedures performed
  • TABLE 1 TOTAL NUMBER OF KNEE REPLACEMENTS, 2021
  • TABLE 2 TOTAL NUMBER OF CORONARY ARTERY BYPASS GRAFT PROCEDURES, 2021
    • 5.2.1.2 Rising focus on R&D
    • 5.2.1.3 Rising focus on effective blood loss management in patients during surgeries
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Side effects and allergic reactions associated with hemostats
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growth opportunities in emerging economies
  • TABLE 3 COST OF SURGICAL PROCEDURES: US VS. INDIA (USD)
    • 5.2.3.2 Growing number of hospitals
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Stringent regulatory framework
    • 5.2.4.2 Dearth of skilled personnel for effective use of hemostats
    • 5.2.4.3 High cost of hemostats
• 5.3 PRICING ANALYSIS
  • 5.3.1 INDICATIVE PRICING MODEL ANALYSIS OF MARKET PLAYERS
  • TABLE 4 INDICATIVE PRICING FOR HEMOSTATS
  • 5.3.2 AVERAGE SELLING PRICE OF HEMOSTATS, BY REGION
  • TABLE 5 AVERAGE SELLING PRICE OF HEMOSTATS
• 5.4 VALUE CHAIN ANALYSIS
  • FIGURE 18 VALUE CHAIN ANALYSIS OF HEMOSTATS MARKET: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
• 5.5 SUPPLY CHAIN ANALYSIS
  • FIGURE 19 HEMOSTATS MARKET: SUPPLY CHAIN ANALYSIS
• 5.6 PATENT ANALYSIS
  • FIGURE 20 PATENT ANALYSIS FOR HEMOSTATS (JANUARY 2013-DECEMBER 2022)
  • 5.6.1 LIST OF MAJOR PATENTS
• 5.7 TRADE ANALYSIS
  • 5.7.1 TRADE ANALYSIS FOR HEMOSTATS
  • TABLE 6 IMPORT DATA FOR HEMOSTATS, BY COUNTRY, 2018-2022 (USD MILLION)
  • TABLE 7 EXPORT DATA FOR HEMOSTATS, BY COUNTRY, 2018-2022 (USD MILLION)
• 5.8 ECOSYSTEM ANALYSIS
  • FIGURE 21 HEMOSTATS MARKET: ECOSYSTEM ANALYSIS
  • 5.8.1 HEMOSTATS MARKET: ROLE IN ECOSYSTEM
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • TABLE 8 HEMOSTATS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT OF NEW ENTRANTS
  • 5.9.2 THREAT OF SUBSTITUTES
  • 5.9.3 BARGAINING POWER OF SUPPLIERS
  • 5.9.4 BARGAINING POWER OF BUYERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 REGULATORY LANDSCAPE
  • TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10.1 NORTH AMERICA
    • 5.10.1.1 US
  • TABLE 13 CLASSIFICATION OF MEDICAL DEVICES BY US FDA
  • FIGURE 22 PREMARKET NOTIFICATION: 510(K) APPROVAL FOR MEDICAL DEVICES
    • 5.10.1.2 Canada
  • FIGURE 23 APPROVAL PROCESS FOR CLASS III MEDICAL DEVICES IN CANADA
  • 5.10.2 EUROPE
  • FIGURE 24 CE APPROVAL PROCESS IN EUROPE FOR HEMOSTATS
  • 5.10.3 ASIA PACIFIC
    • 5.10.3.1 Japan
  • TABLE 14 CLASSIFICATION OF MEDICAL DEVICES AND REVIEWING BODY IN JAPAN
    • 5.10.3.2 China
  • TABLE 15 NMPA MEDICAL DEVICES CLASSIFICATION
    • 5.10.3.3 India
• 5.11 TECHNOLOGY ANALYSIS
• 5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 25 REVENUE SHIFT IN HEMOSTATS MARKET

6 HEMOSTATS MARKET, BY TYPE

• 6.1 INTRODUCTION
  • TABLE 16 HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 17 HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
• 6.2 PRIMARY NOTES
  • 6.2.1 KEY PRIMARY INSIGHTS
• 6.3 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS
  • 6.3.1 GROWING AVAILABILITY OF ORC-BASED HEMOSTATIC AGENTS ACROSS UNTAPPED MARKETS TO DRIVE GROWTH
  • TABLE 18 MAJOR PRODUCTS IN OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET
  • TABLE 19 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET, BY REGION, 2018-2021 (USD MILLION)
  • TABLE 20 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET, BY REGION, 2022-2028 (USD MILLION)
• 6.4 THROMBIN-BASED HEMOSTATS
  • 6.4.1 DEVELOPMENTS IN RECOMBINANT THROMBIN PRODUCTS TO SUPPORT GROWTH
  • TABLE 21 MAJOR PRODUCTS IN THROMBIN-BASED HEMOSTATS MARKET
  • TABLE 22 THROMBIN-BASED HEMOSTATS MARKET, BY REGION, 2018-2021 (USD MILLION)
  • TABLE 23 THROMBIN-BASED HEMOSTATS MARKET, BY REGION, 2022-2028 (USD MILLION)
• 6.5 COMBINATION HEMOSTATS
  • 6.5.1 ADVANCEMENTS IN COMBINATION MATERIALS TO PROPEL MARKET GROWTH
  • TABLE 24 MAJOR PRODUCTS IN COMBINATION HEMOSTATS MARKET
  • TABLE 25 COMBINATION HEMOSTATS MARKET, BY REGION, 2018-2021 (USD MILLION)
  • TABLE 26 COMBINATION HEMOSTATS MARKET, BY REGION, 2022-2028 (USD MILLION)
• 6.6 GELATIN-BASED HEMOSTATS
  • 6.6.1 HIGH ELASTICITY OFFERED BY GELATIN-BASED HEMOSTATS TO BOOST DEMAND
  • TABLE 27 MAJOR PRODUCTS IN GELATIN-BASED HEMOSTATS MARKET
  • TABLE 28 GELATIN-BASED HEMOSTATS MARKET, BY REGION, 2018-2021 (USD MILLION)
  • TABLE 29 GELATIN-BASED HEMOSTATS MARKET, BY REGION, 2022-2028 (USD MILLION)
• 6.7 COLLAGEN-BASED HEMOSTATS
  • 6.7.1 LOW COST AND REDUCED RISK OF DISEASE TRANSMISSION TO PROMOTE ADOPTION OF COLLAGEN-BASED HEMOSTATS
  • TABLE 30 MAJOR PRODUCTS IN COLLAGEN-BASED HEMOSTATS MARKET
  • TABLE 31 COLLAGEN-BASED HEMOSTATS MARKET, BY REGION, 2018-2021 (USD MILLION)
  • TABLE 32 COLLAGEN-BASED HEMOSTATS MARKET, BY REGION, 2022-2028 (USD MILLION)
• 6.8 OTHER HEMOSTATS
  • TABLE 33 OTHER HEMOSTATS MARKET, BY REGION, 2018-2021 (USD MILLION)
  • TABLE 34 OTHER HEMOSTATS MARKET, BY REGION, 2022-2028 (USD MILLION)

7 HEMOSTATS MARKET, BY FORMULATION

• 7.1 INTRODUCTION
  • TABLE 35 HEMOSTATS MARKET, BY FORMULATION, 2018-2021 (USD MILLION)
  • TABLE 36 HEMOSTATS MARKET, BY FORMULATION, 2022-2028 (USD MILLION)
• 7.2 MATRIX & GEL HEMOSTATS
  • 7.2.1 ABILITY OF MATRIX & GEL HEMOSTATS TO ENHANCE PLATELET AGGREGATION TO BOOST MARKET
  • TABLE 37 MATRIX & GEL HEMOSTATS MARKET, BY REGION, 2018-2021 (USD MILLION)
  • TABLE 38 MATRIX & GEL HEMOSTATS MARKET, BY REGION, 2022-2028 (USD MILLION)
• 7.3 SHEET & PAD HEMOSTATS
  • 7.3.1 ABILITY TO CUT SHEET & PAD HEMOSTATS INTO ANY SHAPE OR SIZE TO FUEL ADOPTION
  • TABLE 39 SHEET & PAD HEMOSTATS MARKET, BY REGION, 2018-2021 (USD MILLION)
  • TABLE 40 SHEET & PAD HEMOSTATS MARKET, BY REGION, 2022-2028 (USD MILLION)
• 7.4 SPONGE HEMOSTATS
  • 7.4.1 GROWING ACCEPTANCE OF SPONGE HEMOSTATS TO FUEL UPTAKE
  • TABLE 41 SPONGE HEMOSTATS MARKET, BY REGION, 2018-2021 (USD MILLION)
  • TABLE 42 SPONGE HEMOSTATS MARKET, BY REGION, 2022-2028 (USD MILLION)
• 7.5 POWDER HEMOSTATS
  • 7.5.1 ABILITY TO SPRAY POWDER FORMULATIONS DIRECTLY ON WOUNDS TO FUEL DEMAND
  • TABLE 43 POWDER HEMOSTATS MARKET, BY REGION, 2018-2021 (USD MILLION)
  • TABLE 44 POWDER HEMOSTATS MARKET, BY REGION, 2022-2028 (USD MILLION)

8 HEMOSTATS MARKET, BY APPLICATION

• 8.1 INTRODUCTION
  • TABLE 45 HEMOSTATS MARKET, BY APPLICATION, 2018-2021 (USD MILLION)
  • TABLE 46 HEMOSTATS MARKET, BY APPLICATION, 2022-2028 (USD MILLION)
• 8.2 PRIMARY NOTES
  • 8.2.1 KEY PRIMARY INSIGHTS
• 8.3 ORTHOPEDIC SURGERY
  • 8.3.1 INCREASING INCIDENCE OF SPORTS INJURIES TO SUPPORT MARKET GROWTH
  • TABLE 47 NUMBER OF KNEE & HIP REPLACEMENTS, 2021
  • TABLE 48 HEMOSTATS MARKET FOR ORTHOPEDIC SURGERY, BY REGION, 2018-2021 (USD MILLION)
  • TABLE 49 HEMOSTATS MARKET FOR ORTHOPEDIC SURGERY, BY REGION, 2022-2028 (USD MILLION)
• 8.4 GENERAL SURGERY
  • 8.4.1 INCREASING NUMBER OF HERNIA REPAIR PROCEDURES TO DRIVE GROWTH
  • TABLE 50 TOTAL NUMBER OF INGUINAL HERNIA REPAIR PROCEDURES, 2021
  • TABLE 51 HEMOSTATS MARKET FOR GENERAL SURGERY, BY REGION, 2018-2021 (USD MILLION)
  • TABLE 52 HEMOSTATS MARKET FOR GENERAL SURGERY, BY REGION, 2022-2028 (USD MILLION)
• 8.5 NEUROLOGICAL SURGERY
  • 8.5.1 GROWING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH
  • TABLE 53 HEMOSTATS MARKET FOR NEUROLOGICAL SURGERY, BY REGION, 2018-2021 (USD MILLION)
  • TABLE 54 HEMOSTATS MARKET FOR NEUROLOGICAL SURGERY, BY REGION, 2022-2028 (USD MILLION)
• 8.6 CARDIOVASCULAR SURGERY
  • 8.6.1 RISING PREVALENCE OF CVD TO DRIVE ADOPTION OF HEMOSTATS
  • TABLE 55 HEMOSTATS MARKET FOR CARDIOVASCULAR SURGERY, BY REGION, 2018-2021 (USD MILLION)
  • TABLE 56 HEMOSTATS MARKET FOR CARDIOVASCULAR SURGERY, BY REGION, 2022-2028 (USD MILLION)
• 8.7 RECONSTRUCTIVE SURGERY
  • 8.7.1 GROWING NUMBER OF COSMETIC SURGERIES TO SUPPORT MARKET GROWTH
  • TABLE 57 HEMOSTATS MARKET FOR RECONSTRUCTIVE SURGERY, BY REGION, 2018-2021 (USD MILLION)
  • TABLE 58 HEMOSTATS MARKET FOR RECONSTRUCTIVE SURGERY, BY REGION, 2022-2028 (USD MILLION)
• 8.8 GYNECOLOGICAL SURGERY
  • 8.8.1 GROWING USE OF HEMOSTATS IN C-SECTION PROCEDURES TO CONTROL SURGICAL BLEEDING TO SUPPORT GROWTH
  • TABLE 59 HEMOSTATS MARKET FOR GYNECOLOGICAL SURGERY, BY REGION, 2018-2021 (USD MILLION)
  • TABLE 60 HEMOSTATS MARKET FOR GYNECOLOGICAL SURGERY, BY REGION, 2022-2028 (USD MILLION)
• 8.9 OTHER SURGICAL APPLICATIONS
  • TABLE 61 HEMOSTATS MARKET FOR OTHER SURGICAL APPLICATIONS, BY REGION, 2018-2021 (USD MILLION)
  • TABLE 62 HEMOSTATS MARKET FOR OTHER SURGICAL APPLICATIONS, BY REGION, 2022-2028 (USD MILLION)

9 HEMOSTATS MARKET, BY REGION

• 9.1 INTRODUCTION
  • TABLE 63 HEMOSTATS MARKET, BY REGION, 2018-2021 (USD MILLION)
  • TABLE 64 HEMOSTATS MARKET, BY REGION, 2022-2028 (USD MILLION)
• 9.2 NORTH AMERICA
  • FIGURE 26 NORTH AMERICA: HEMOSTATS MARKET SNAPSHOT
  • TABLE 65 NORTH AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2018-2021 (USD MILLION)
  • TABLE 66 NORTH AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2022-2028 (USD MILLION)
  • TABLE 67 NORTH AMERICA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 68 NORTH AMERICA: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • TABLE 69 NORTH AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2018-2021 (USD MILLION)
  • TABLE 70 NORTH AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2022-2028 (USD MILLION)
  • TABLE 71 NORTH AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2018-2021 (USD MILLION)
  • TABLE 72 NORTH AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2022-2028 (USD MILLION)
  • 9.2.1 NORTH AMERICA: RECESSION IMPACT
  • 9.2.2 US
    • 9.2.2.1 Strong healthcare infrastructure to support uptake of hemostats
  • TABLE 73 US: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 74 US: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • 9.2.3 CANADA
    • 9.2.3.1 Growing geriatric population and increasing volume of surgeries to drive demand for hemostats
  • TABLE 75 SURGICAL PROCEDURES PERFORMED IN CANADA, 2021
  • TABLE 76 CANADA: KEY MACROINDICATORS
  • TABLE 77 CANADA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 78 CANADA: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
• 9.3 EUROPE
  • TABLE 79 EUROPE: HEMOSTATS MARKET, BY COUNTRY, 2018-2021 (USD MILLION)
  • TABLE 80 EUROPE: HEMOSTATS MARKET, BY COUNTRY, 2022-2028 (USD MILLION)
  • TABLE 81 EUROPE: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 82 EUROPE: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • TABLE 83 EUROPE: HEMOSTATS MARKET, BY FORMULATION, 2018-2021 (USD MILLION)
  • TABLE 84 EUROPE: HEMOSTATS MARKET, BY FORMULATION, 2022-2028 (USD MILLION)
  • TABLE 85 EUROPE: HEMOSTATS MARKET, BY APPLICATION, 2018-2021 (USD MILLION)
  • TABLE 86 EUROPE: HEMOSTATS MARKET, BY APPLICATION, 2022-2028 (USD MILLION)
  • 9.3.1 EUROPE: RECESSION IMPACT
  • 9.3.2 GERMANY
    • 9.3.2.1 High healthcare expenditure in Germany to favor market growth
  • TABLE 87 SURGICAL PROCEDURES PERFORMED IN GERMANY, 2021
  • TABLE 88 GERMANY: KEY MACROINDICATORS
  • TABLE 89 GERMANY: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 90 GERMANY: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • 9.3.3 UK
    • 9.3.3.1 Growing volume of hernia repair and cardiovascular surgeries to drive market growth
  • TABLE 91 SURGICAL PROCEDURES PERFORMED IN UK, 2021
  • TABLE 92 UK: KEY MACROINDICATORS
  • TABLE 93 UK: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 94 UK: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • 9.3.4 FRANCE
    • 9.3.4.1 Presence of well-established healthcare system to propel market growth
  • TABLE 95 SURGICAL PROCEDURES PERFORMED IN FRANCE, 2021
  • TABLE 96 FRANCE: KEY MACROINDICATORS
  • TABLE 97 FRANCE: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 98 FRANCE: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • 9.3.5 ITALY
    • 9.3.5.1 Increasing volume of surgeries to drive demand for hemostats
  • TABLE 99 SURGICAL PROCEDURES PERFORMED IN ITALY, 2021
  • TABLE 100 ITALY: KEY MACROINDICATORS
  • TABLE 101 ITALY: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 102 ITALY: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • 9.3.6 SPAIN
    • 9.3.6.1 Growing healthcare budget and rising efforts to boost local manufacturing of medical products to drive market growth
  • TABLE 103 SURGICAL PROCEDURES PERFORMED IN SPAIN, 2021
  • TABLE 104 SPAIN: KEY MACROINDICATORS
  • TABLE 105 SPAIN: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 106 SPAIN: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • 9.3.7 RUSSIA
    • 9.3.7.1 Long-term healthcare investment initiatives by government to support market growth
  • TABLE 107 RUSSIA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 108 RUSSIA: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • 9.3.8 SWITZERLAND
    • 9.3.8.1 Increasing public health insurance coverage to drive number of surgical procedures
  • TABLE 109 SURGICAL PROCEDURES PERFORMED IN SWITZERLAND, 2021
  • TABLE 110 SWITZERLAND: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 111 SWITZERLAND: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • 9.3.9 BELGIUM
    • 9.3.9.1 Increasing demand for value-based healthcare services to drive market growth
  • TABLE 112 SURGICAL PROCEDURES PERFORMED IN BELGIUM, 2021
  • TABLE 113 BELGIUM: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 114 BELGIUM: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • 9.3.10 REST OF EUROPE
  • TABLE 115 REST OF EUROPE: PERCENTAGE OF GDP ON HEALTHCARE EXPENDITURE, BY COUNTRY
  • TABLE 116 REST OF EUROPE: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 117 REST OF EUROPE: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
• 9.4 ASIA PACIFIC
  • FIGURE 27 ASIA PACIFIC: HEMOSTATS MARKET SNAPSHOT
  • TABLE 118 ASIA PACIFIC: HEMOSTATS MARKET, BY COUNTRY, 2018-2021 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: HEMOSTATS MARKET, BY COUNTRY, 2022-2028 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 121 ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • TABLE 122 ASIA PACIFIC: HEMOSTATS MARKET, BY FORMULATION, 2018-2021 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: HEMOSTATS MARKET, BY FORMULATION, 2022-2028 (USD MILLION)
  • TABLE 124 ASIA PACIFIC: HEMOSTATS MARKET, BY APPLICATION, 2018-2021 (USD MILLION)
  • TABLE 125 ASIA PACIFIC: HEMOSTATS MARKET, BY APPLICATION, 2022-2028 (USD MILLION)
  • 9.4.1 ASIA PACIFIC: RECESSION IMPACT
  • 9.4.2 CHINA
    • 9.4.2.1 Growing number of hospitals and healthcare policy reforms to drive growth
  • TABLE 126 CHINA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 127 CHINA: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • 9.4.3 JAPAN
    • 9.4.3.1 Strong healthcare system and rising geriatric population to support market growth
  • TABLE 128 JAPAN: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 129 JAPAN: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • 9.4.4 INDIA
    • 9.4.4.1 Rising healthcare awareness and favorable government support to propel market growth
  • TABLE 130 INDIA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 131 INDIA: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • 9.4.5 AUSTRALIA
    • 9.4.5.1 Rising prevalence of chronic diseases to drive market growth
  • TABLE 132 AUSTRALIA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 133 AUSTRALIA: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • 9.4.6 SOUTH KOREA
    • 9.4.6.1 Growing number of cosmetic surgeries to drive demand for hemostats
  • TABLE 134 SURGICAL PROCEDURES IN SOUTH KOREA, 2021
  • TABLE 135 SOUTH KOREA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 136 SOUTH KOREA: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • 9.4.7 SINGAPORE
    • 9.4.7.1 Government initiatives to promote healthcare services to support market growth
  • TABLE 137 SINGAPORE: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 138 SINGAPORE: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • 9.4.8 NEW ZEALAND
    • 9.4.8.1 Increasing number of hip fractures to propel market growth
  • TABLE 139 NEW ZEALAND: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 140 NEW ZEALAND: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • 9.4.9 INDONESIA
    • 9.4.9.1 Lucrative growth opportunities for players to boost market
  • TABLE 141 INDONESIA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 142 INDONESIA: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • 9.4.10 MALAYSIA
    • 9.4.10.1 Low healthcare costs, modern medical technology, and highly qualified doctors to favor market growth
  • TABLE 143 MALAYSIA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 144 MALAYSIA: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • 9.4.11 REST OF ASIA PACIFIC
  • TABLE 145 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 146 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
• 9.5 LATIN AMERICA
  • TABLE 147 LATIN AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2018-2021 (USD MILLION)
  • TABLE 148 LATIN AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2022-2028 (USD MILLION)
  • TABLE 149 LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 150 LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • TABLE 151 LATIN AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2018-2021 (USD MILLION)
  • TABLE 152 LATIN AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2022-2028 (USD MILLION)
  • TABLE 153 LATIN AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2018-2021 (USD MILLION)
  • TABLE 154 LATIN AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2022-2028 (USD MILLION)
  • 9.5.1 LATIN AMERICA: RECESSION IMPACT
  • 9.5.2 BRAZIL
    • 9.5.2.1 Brazil to dominate Latin American market for hemostats
  • TABLE 155 BRAZIL: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 156 BRAZIL: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • 9.5.3 MEXICO
    • 9.5.3.1 Low-cost surgeries to drive medical tourism in Mexico
  • TABLE 157 MEXICO: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 158 MEXICO: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • 9.5.4 REST OF LATIN AMERICA
  • TABLE 159 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 160 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
• 9.6 MIDDLE EAST & AFRICA
  • 9.6.1 STRENGTHENING OF HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
  • TABLE 161 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE, 2018-2021 (USD MILLION)
  • TABLE 162 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE, 2022-2028 (USD MILLION)
  • TABLE 163 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY FORMULATION, 2018-2021 (USD MILLION)
  • TABLE 164 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY FORMULATION, 2022-2028 (USD MILLION)
  • TABLE 165 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY APPLICATION, 2018-2021 (USD MILLION)
  • TABLE 166 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY APPLICATION, 2022-2028 (USD MILLION)
  • 9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HEMOSTATS MARKET
  • TABLE 167 OVERVIEW OF STRATEGIES DEPLOYED BY KEY HEMOSTAT MANUFACTURING COMPANIES
• 10.3 REVENUE ANALYSIS
  • FIGURE 28 REVENUE ANALYSIS OF TOP PLAYERS IN HEMOSTATS MARKET (2018-2022)
• 10.4 MARKET SHARE ANALYSIS
  • FIGURE 29 MARKET SHARE ANALYSIS OF TOP PLAYERS IN HEMOSTATS MARKET (2022)
  • TABLE 168 HEMOSTATS MARKET: DEGREE OF COMPETITION
• 10.5 COMPANY EVALUATION MATRIX
  • 10.5.1 LIST OF EVALUATED VENDORS
  • 10.5.2 STARS
  • 10.5.3 EMERGING LEADERS
  • 10.5.4 PERVASIVE PLAYERS
  • 10.5.5 PARTICIPANTS
  • FIGURE 30 HEMOSTATS MARKET: COMPANY EVALUATION MATRIX (2022)
  • 10.5.6 COMPANY FOOTPRINT
    • 10.5.6.1 Product & regional footprint analysis
  • FIGURE 31 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN HEMOSTATS MARKET
  • TABLE 169 HEMOSTATS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
  • TABLE 170 COMPANY FOOTPRINT, BY TYPE
  • TABLE 171 COMPANY FOOTPRINT, BY REGION
• 10.6 START-UP/SME EVALUATION MATRIX
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 RESPONSIVE COMPANIES
  • 10.6.3 DYNAMIC COMPANIES
  • 10.6.4 STARTING BLOCKS
  • FIGURE 32 HEMOSTATS MARKET: START-UP/SME EVALUATION MATRIX (2022)
• 10.7 COMPETITIVE SCENARIO
  • 10.7.1 PRODUCT LAUNCHES & APPROVALS
  • TABLE 172 KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2018-OCTOBER 2023)
  • 10.7.2 DEALS
  • TABLE 173 KEY DEALS (JANUARY 2018-OCTOBER 2023)
  • 10.7.3 OTHER KEY DEVELOPMENTS
  • TABLE 174 OTHER KEY DEVELOPMENTS (JANUARY 2018-OCTOBER 2023)

11 COMPANY PROFILES

• (Business overview, Products offered, Recent developments & MnM View)**
• 11.1 KEY PLAYERS
  • 11.1.1 JOHNSON & JOHNSON
  • TABLE 175 JOHNSON & JOHNSON: BUSINESS OVERVIEW
  • FIGURE 33 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2022)
  • 11.1.2 BAXTER INTERNATIONAL
  • TABLE 176 BAXTER INTERNATIONAL: BUSINESS OVERVIEW
  • FIGURE 34 BAXTER INTERNATIONAL: COMPANY SNAPSHOT (2022)
  • 11.1.3 PFIZER INC.
  • TABLE 177 PFIZER INC.: BUSINESS OVERVIEW
  • FIGURE 35 PFIZER INC.: COMPANY SNAPSHOT (2022)
  • 11.1.4 B. BRAUN SE
  • TABLE 178 B. BRAUN SE: BUSINESS OVERVIEW
  • FIGURE 36 B. BRAUN SE: COMPANY SNAPSHOT (2022)
  • 11.1.5 BECTON, DICKINSON AND COMPANY
  • TABLE 179 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
  • FIGURE 37 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
  • 11.1.6 TELEFLEX INCORPORATED
  • TABLE 180 TELEFLEX INCORPORATED: BUSINESS OVERVIEW
  • FIGURE 38 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2022)
  • 11.1.7 MEDTRONIC PLC
  • TABLE 181 MEDTRONIC PLC: BUSINESS OVERVIEW
  • FIGURE 39 MEDTRONIC PLC: COMPANY SNAPSHOT (2022)
  • 11.1.8 HEMOSTASIS, LLC
  • TABLE 182 HEMOSTASIS, LLC: BUSINESS OVERVIEW
  • 11.1.9 STRYKER CORPORATION
  • TABLE 183 STRYKER CORPORATION: BUSINESS OVERVIEW
  • FIGURE 40 STRYKER CORPORATION: COMPANY SNAPSHOT (2022)
  • 11.1.10 INTEGRA LIFESCIENCES
  • TABLE 184 INTEGRA LIFESCIENCES: BUSINESS OVERVIEW
  • FIGURE 41 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2022)
  • 11.1.11 ADVANCED MEDICAL SOLUTIONS GROUP PLC
  • TABLE 185 ADVANCED MEDICAL SOLUTIONS GROUP PLC: BUSINESS OVERVIEW
  • FIGURE 42 ADVANCED MEDICAL SOLUTIONS GROUP PLC: COMPANY SNAPSHOT (2022)
  • 11.1.12 SAMYANG HOLDINGS CORPORATION
  • TABLE 186 SAMYANG CORPORATION: BUSINESS OVERVIEW
  • FIGURE 43 SAMYANG CORPORATION: COMPANY SNAPSHOT (2022)
• *Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
• 11.2 OTHER PLAYERS
  • 11.2.1 MARINE POLYMER TECHNOLOGIES, INC.
  • 11.2.2 GELITA MEDICAL GMBH
  • 11.2.3 DILON TECHNOLOGIES, INC.
  • 11.2.4 BETATECH MEDICAL
  • 11.2.5 MERIL LIFE SCIENCES PVT. LTD.
  • 11.2.6 BIOCER ENTWICKLUNGS-GMBH
  • 11.2.7 UNILENE
  • 11.2.8 KATSAN MEDICAL DEVICES
  • 11.2.9 TRICOL BIOMEDICAL
  • 11.2.10 3-D MATRIX MEDICAL TECHNOLOGY
  • 11.2.11 HEMOSTAT MEDICAL GMBH
  • 11.2.12 MEDTRADE PRODUCTS LIMITED
  • 11.2.13 ALTAYLAR MEDICAL

12 APPENDIX

• 12.1 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.2 CUSTOMIZATION OPTIONS
• 12.3 RELATED REPORTS
• 12.4 AUTHOR DETAILS